查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117037

非酒精性脂肪肝疾病市場：依藥物類別、給藥途徑、分銷方式、年齡層、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Non-Alcoholic Fatty Liver Disease Market, By Drug Class, By Route of Administration, By Distribution, By Age Group, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 258 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，非酒精性脂肪肝 (NAFLD) 市值將達到 34.052 億美元，並將在 2026 年至 2033 年期間以 16.3% 的複合年成長率成長。

非酒精性脂肪肝病 (NAFLD) 的治療包括針對病理性脂肪堆積、發炎和代謝功能障礙的藥物，以及針對肝纖維化的藥物，例如抗氧化劑、降血脂藥物、胰島素增敏劑藥物、FXR促效劑、雙胍類藥物和抗纖維化藥物。大多數藥物為口服給藥，但注射療法的需求日益成長，包括腸促胰素和聯合治療。

理想的治療方法是根據纖維化進展階段和相關的代謝異常對患者進行分層。此外，治療方案的選擇應基於切片檢查或非侵入性評估對纖維化進展的確認，重點在於緩解疾病的證據，而不僅僅是脂肪含量的降低。據美國食品藥物管理局（FDA）稱，MASLD影響著美國約6%的成年人，這使得市場需要轉向採用更個人化的治療方法，為患者提供更合適的治療。

非酒精性脂肪肝病（MASLD）市場－市場動態

改善纖維化可以帶來超越代謝風險管理的治療方案。

目前的臨床管理趨勢正從單純的減重及相關疾病（如糖尿病和血脂異常症）轉向治療肝損傷本身。法規環境的重點已轉向旨在解決肝纖維化和脂肪性肝炎的臨床試驗，這對於緩解疾病藥物市場的商業性成功至關重要，也凸顯了專科醫生處方的重要性。此外，由於研發公司必須證明組織學改善或檢驗的非侵入性改善，並證明其長期安全性，因此需要更高水準的證據。 2025年8月，FDA批准了Semaglutide用於治療MASLD。這是因為接受該藥物治療的患者中有63%未出現纖維化進展，且其MASLD已緩解。這項發現對後續針對目標族群的臨床試驗以及肝纖維化市場的競爭產生了重大影響。

非酒精性脂肪肝疾病市場－市場區隔分析：

全球非酒精性脂肪肝疾病市場按藥物類別、給藥途徑、分銷形式、年齡層和地區進行細分。

在所提出的藥物類別分類中，纖維化治療方案佔據了最具發展前景的戰略地位，其中疾病修正治療已成為一項明確的未滿足需求。因此，那些已被證實能夠透過針對疾病的特定組織學階段來抑制疾病進展的療法具有最大的差異化潛力。另一方面，抗氧化劑、降血脂藥、噻唑烷二酮類藥物和雙胍類藥物的應用範圍相對有限，因為它們的適應症與氧化壓力的緩解而非緩解疾病更相關。 FXR促效劑也對肝纖維化有影響，但由於近期監管的擔憂，其研發受到限制。 Rezdiffra試驗對此概念進行了廣泛的積極評估，證實了其對917名F2或F3期患者的療效，此後，纖維化標靶療法得以確立。臨床試驗的證據在塑造藥物的整體定位和獲得專家認可方面發揮著至關重要的作用，且不受地域限制。

就給藥途徑而言，口服給藥顯然更勝一籌，因為其給藥時間方便，且患者整體遵守用藥優於常規注射。 Rezdiffra 每日服用一次，這進一步凸顯了每日一次治療在整體纖維化適應症中的潛力。腸外給藥適用於達到更高的血中濃度並利用腸促胰素效應，但需要額外的給藥程序。具有緩解疾病潛力的 GLP-1調變器的出現，正促使人們重新檢視給藥途徑的二元性。在該適應症中，一項為期 240 週的Semaglutide試驗旨在證明其在組織學改善之外的臨床療效，該試驗需要獲得 FDA 批准，預計於 2025 年完成。口服治療在便利性方面可能仍將優於腸外治療，但腸外治療或許能夠透過發揮緩解疾病作用來鞏固其市場地位。

非酒精性脂肪肝 (NAFLD) 市場—區域洞察

憑藉成熟的醫藥市場、肝病學專業知識和監管活動，北美已成為非酒精性脂肪肝病 (NAFLD) 治療領域的重要商業性標竿。在美國，專家技術和代謝疾病診療基礎設施的整合，促進了肝臟特異性療法在現有診療路徑中的應用。此外，美國食品藥物管理局 (FDA) 於 2025 年批准Semaglutide用於治療伴有肝纖維化的非酒精性脂肪肝病 (MASLD)，這將拓展美國市場的治療選擇，並與其他靶向肝纖維化的藥物形成直接的比較標準。肝纖維化在美國是一種高發病，根據 FDA 估計，約有 1,490 萬美國人患有 MASLD。北美將繼續在產品上市、專家採納和商業性成功方面發揮重要作用。

歐洲正在崛起，成為美國以外的監管和臨床開發中心，無論是在獲得批准還是累積臨床證據方面。歐洲藥品管理局 (EMA) 於 2025 年 6 月有條件批准了 Rezdiffra 上市，歐盟委員會於同年 8 月授予其上市許可。這是歐洲首​​個核准的 MASLD 治療藥物，其監管決定基於主要臨床試驗的積極數據。在該試驗中，接受 100 毫克 Rezdiffra 治療的患者中有 29% 的纖維化症狀有所改善，且治療組未觀察到 MASLD 病情惡化。然而，EMA 在核准過程中要求提交更長期的證據。因此，歐洲是一個具有巨大商業性和臨床價值的地區，但各國衛生技術評估 (HTA) 的差異將影響每種療法的相對成功率。

目錄

第1章：非酒精性脂肪肝疾病市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：非酒精性脂肪肝疾病的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：非酒精性脂肪肝疾病的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章 非酒精性脂肪肝疾病市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：非酒精性脂肪肝疾病的市場趨勢

  • 非酒精性脂肪肝疾病市佔率分析，2025 年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 非酒精性脂肪肝疾病市場：依藥物類別分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類別分類
    • THR-B促效劑
    • GLP-1受體促效劑
    • 抗纖維化藥物
    • FXR促效劑
    • 降血脂藥物
    • 胰島素增敏劑藥物
    • 抗氧化劑
    • 其他

第8章 非酒精性脂肪肝疾病市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 腸外
    • 口服

第9章 非酒精性脂肪肝疾病市場：依通路分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 零售藥房
    • 醫院藥房
    • 網路藥房
    • 其他

第10章 非酒精性脂肪肝疾病市場：依年齡層分類

  • 概述
    • 按年齡層分類的市佔率分析
    • 老年人
    • 成人
    • 兒童

第11章 非酒精性脂肪肝疾病市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章 主要供應商分析：非酒精性脂肪肝疾病產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Madrigal Pharmaceuticals, Inc.
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd./89bio
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Inventiva SA
    • AstraZeneca plc
    • GSK plc
    • Viking Therapeutics, Inc.
    • Altimmune, Inc.
    • Sagimet Biosciences Inc.
    • Terns Pharmaceuticals, Inc.
    • Galectin Therapeutics Inc.
    • Galmed Pharmaceuticals Ltd.
    • NGM Biopharmaceuticals, Inc.
    • Bristol Myers Squibb
    • Zydus Lifesciences Ltd.
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7310

Non-Alcoholic Fatty Liver Disease Market size was valued at US$ 3,405.2 Million in 2025, expanding at a CAGR of 16.3% from 2026 to 2033.

Non-alcoholic fatty liver disease (NAFLD) encompasses pharmaceuticals for the treatment of pathological fat accumulation, inflammation, and metabolic dysfunction, as well as therapies for liver fibrosis, including antioxidants, lipid-lowering agents, thiazolidinediones, FXR agonists, biguanides, and antifibrotic agents. Most drugs are administered orally, and there is a need for injectable therapies, including incretin-based and combination approaches.

The ideal approach is to stratify patients according to the stage of fibrosis and the associated metabolic disorders. In addition, the choice of therapy is based on biopsy-proven or non-invasive assessment of fibrosis progression, with an emphasis on the need for evidence of disease modification rather than only fat content reduction. According to the FDA, MASLD affects about 6% of U.S. adults, determining the need for the market to shift to a more individualized approach to treating patients with appropriate therapies.

Non-Alcoholic Fatty Liver Disease Market- Market Dynamics

Fibrosis Modification Moves Treatment Beyond Metabolic Risk Control

The current trend in clinical management is shifting toward the treatment of liver damage, not only weight loss or related conditions such as diabetes or dyslipidemia. The regulatory environment now focuses on trials targeting the resolution of fibrosis and steatohepatitis, which is an important differentiator for commercial success in the market for disease-modifying agents, increasing the relevance of specialist prescribers. Additionally, a higher level of evidence is required since the developer should provide either histological or validated non-invasive improvement, and long-term safety should be demonstrated. The FDA approved semaglutide for the treatment of MASLD in August 2025, as among the participants who received the drug, there was a resolution of MASLD without progression of fibrosis noted in 63%. The findings significantly impacted the subsequent wave of clinical trials and competition in the fibrosis market in the studied population.

Non-Alcoholic Fatty Liver Disease Market- Segmentation Analysis:

The Global Non-Alcoholic Fatty Liver Disease Market is segmented on the basis of Drug Class, Route of Administration, Distribution, Age Group, and Region.

Within the given drug-class segmentation, treatment options for fibrosis possess the most promising strategic positioning, of which disease modification emerged as the clearly stated unmet medical need. Therefore, therapies that have been proven to reduce progression by targeting the specific histological stages of the disease possess the biggest differential potential. Meanwhile, antioxidants, lipid-lowering agents, TZDs, and biguanides have a more limited scope due to their target indications, which are closely linked to addressing oxidative stress rather than disease modification. Although FXR agonists also affect liver fibrosis, their development has been limited due to recent regulatory concerns. Fibrosis-targeted treatment modalities were established due to the large and positive readout for the concept following the Rezdiffra study, which enrolled 917 patients with F2 or F3 and confirmed efficacy. Evidence from clinical trials plays the biggest role in shaping the generic positioning and specialist perceptions across regions.

Regarding the route of administration, oral is clearly superior due to the convenience of the dosing schedule, as well as overall simpler compliance compared to regular injections. Rezdiffra is taken once per day, which further highlights the potential for once-daily treatment across the fibrosis indications. Parenteral approaches are suitable for achieving greater exposure and utilizing the incretin effect, but they involve additional administration steps. The split in the route of administration is being challenged due to the launch of GLP-1 modulators, which possess disease-modifying potential. Within the indication, semaglutide's 240-week trial to demonstrate clinical benefit beyond histological improvement now needs to be approved by the FDA in 2025. Orally administered therapy will maintain the convenience differential over parenteral treatments, but the latter can leverage disease modification to increase the positioning.

Non-Alcoholic Fatty Liver Disease Market- Geographical Insights

A mature pharmaceutical market, hepatology expertise, and regulatory activity make North America the key commercial reference center for NAFLD therapies. The United States affords a combination of specialist input and metabolic care infrastructure, facilitating the arrival of liver-specific therapeutics within an established care pathway. In addition, the FDA approval of semaglutide for MASLD in the United States in 2025 provides both therapy options for the U.S. market and a direct comparison for other fibrosis-targeting agents. Fibrosis is a prevalent condition within the United States, with the FDA estimating that 14.9 million Americans have MASLD. North America is likely to remain the region of key influence for product launches, specialty uptake, and commercial success.

Europe is emerging as an alternative regulatory and clinical-development hub to the United States, both for the purposes of securing approvals and building clinical evidence. The EMA granted conditional approval to Rezdiffra in June 2025, with marketing authorization granted by the European Commission in August of the same year. It is the first MASLD therapy available in Europe, with positive data from its pivotal trial informing the regulatory decision. Within the trial, treatment of patients with Rezdiffra at 100 mg demonstrated improvements in fibrosis for 29% of patients with no worsening of MASLD in the treatment group, although longer-term evidence was requested by the EMA during the approval process. As such, Europe represents a region of significant commercial and clinical value, although variations in health technology assessment between countries will dictate the relative success of different therapies.

Non-Alcoholic Fatty Liver Disease Market- Competitive Landscape:

Competition is now focused on greater proof of fibrosis improvement, metabolic benefit, route of administration convenience, and the capacity to target a substantial number of specialists compared to the legacy management of symptoms. Madrigal's resmetirom created a precedent for an oral and liver-directed approach, while Novo Nordisk's semaglutide's MASLD indication made the company's injectable platform more attractive. Development is also concentrated on obesity, diabetes, and liver disease mechanisms, allowing the companies to capitalize on infrastructure and physician relationships. Novo Nordisk employs 69,505 workers globally as of 2025, exemplifying the investment required to navigate the development, manufacturing, and regulatory approval processes across multiple regions. The competitive position within the industry is now based on metabolic disease platforms, established liver endpoints, and commercial reach.

Recent Developments:

In August 2025, Novo Nordisk's Wegovy (semaglutide) received FDA approval for the treatment of noncirrhotic MASH with moderate-to-advanced fibrosis, thereby expanding its therapeutic area to include liver disease and competing with resmetirom in the fibrosis-focused MASH treatment landscape.

In August 2025, the European Commission granted conditional marketing authorization to Madrigal Pharmaceuticals for Rezdiffra (resmetirom) for the treatment of noncirrhotic MASH and moderate-to-advanced fibrosis in adults, thereby bringing its liver-directed drug therapy to the European Union.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Madrigal Pharmaceuticals, Inc.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd. / 89bio
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Inventiva S.A.
  • AstraZeneca plc
  • GSK plc
  • Viking Therapeutics, Inc.
  • Altimmune, Inc.
  • Sagimet Biosciences Inc.
  • Terns Pharmaceuticals, Inc.
  • Galectin Therapeutics Inc.
  • Galmed Pharmaceuticals Ltd.
  • NGM Biopharmaceuticals, Inc.
  • Bristol Myers Squibb
  • Zydus Lifesciences Ltd.
  • Others

GLOBALNON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

  • THR-B Agonists
  • GLP-1 Receptor Agonists
  • Antifibrotic Agents
  • FXR Agonists
  • Lipid-Lowering Agents
  • Thiazolidinediones
  • Antioxidants
  • Others

GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Parenteral
  • Oral

GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033

  • Geriatric
  • Adults
  • Pediatric

GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Non-Alcoholic Fatty Liver Disease Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Non-Alcoholic Fatty Liver Disease Key Market Trends

  • 3.1. Non-Alcoholic Fatty Liver Disease Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Non-Alcoholic Fatty Liver Disease Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Non-Alcoholic Fatty Liver Disease Market Opportunities
  • 3.4. Non-Alcoholic Fatty Liver Disease Market Future Trends

4. Non-Alcoholic Fatty Liver Disease Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Non-Alcoholic Fatty Liver Disease Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Non-Alcoholic Fatty Liver Disease Market Landscape

  • 6.1. Non-Alcoholic Fatty Liver Disease Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Non-Alcoholic Fatty Liver Disease Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
    • 7.1.2. THR-B Agonists
    • 7.1.3. GLP-1 Receptor Agonists
    • 7.1.4. Antifibrotic Agents
    • 7.1.5. FXR Agonists
    • 7.1.6. Lipid-Lowering Agents
    • 7.1.7. Thiazolidinediones
    • 7.1.8. Antioxidants
    • 7.1.9. Others

8. Non-Alcoholic Fatty Liver Disease Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Non-Alcoholic Fatty Liver Disease Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies
    • 9.1.5. Others

10. Non-Alcoholic Fatty Liver Disease Market - By Age Group

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Age Group, 2025 & 2033 (%)
    • 10.1.2. Geriatric
    • 10.1.3. Adults
    • 10.1.4. Pediatric

11. Non-Alcoholic Fatty Liver Disease Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Non-Alcoholic Fatty Liver Disease Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Non-Alcoholic Fatty Liver Disease Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Madrigal Pharmaceuticals, Inc.
    • 12.2.2. Novo Nordisk A/S
    • 12.2.3. Eli Lilly and Company
    • 12.2.4. F. Hoffmann-La Roche Ltd. / 89bio
    • 12.2.5. Gilead Sciences, Inc.
    • 12.2.6. AbbVie Inc.
    • 12.2.7. Pfizer Inc.
    • 12.2.8. Boehringer Ingelheim International GmbH
    • 12.2.9. Inventiva S.A.
    • 12.2.10. AstraZeneca plc
    • 12.2.11. GSK plc
    • 12.2.12. Viking Therapeutics, Inc.
    • 12.2.13. Altimmune, Inc.
    • 12.2.14. Sagimet Biosciences Inc.
    • 12.2.15. Terns Pharmaceuticals, Inc.
    • 12.2.16. Galectin Therapeutics Inc.
    • 12.2.17. Galmed Pharmaceuticals Ltd.
    • 12.2.18. NGM Biopharmaceuticals, Inc.
    • 12.2.19. Bristol Myers Squibb
    • 12.2.20. Zydus Lifesciences Ltd.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us